Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1413431-07-8
Molecular formula
C24H19D9N2O3
Molecular weight
401.5 g/mol
Drug class
CFTR potentiatordeuterated ivacaftor component of vanzacaftor/deutivacaftor/tezacaftor combination
Mechanism of action
Enhances the open probability of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels at the cell surface. Deuteration modifies metabolic stability; its clinical use is as part of a fixed triple combination, not as a standalone API.
Indications / reported uses
Component of the fixed combination ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for treatment of cystic fibrosis in eligible patients aged 6 years and older who have at least one responsive CFTR mutation, under the current product label
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Deutivacaftor Environmental Risk Assessment (ERA) (the Deutivacaftor ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.